DrugComb

DrugComb provides a centralized resource for aggregation, standardization, analysis, and predictive modeling of high-throughput cancer drug combination screening data to identify synergistic combinations and inform therapeutic strategies.

Key Features:

• Data accumulation and standardization: Aggregates and harmonizes results from high-throughput drug combination screening studies into standardized data formats.
• Extensive data repository: Hosts a dataset comprising 437,932 drug combinations tested across diverse cancer cell lines.
• Data visualization and computational tools: Provides tools for visualization and computational analysis of drug combination screening data.
• Crowdsourced data curation: Supports community deposition and curation of drug combination screening results to expand and enrich the database.
• Predictive modeling: Implements linear regression approaches that use chemical fingerprints as predictors to estimate sensitivity of drug combinations.
• Developed by FIMM: Curated and maintained by the Finnish Institute of Molecular Medicine (FIMM).

Scientific Applications:

• Enhancing efficacy and reducing toxicity: Identifies synergistic combinations that can improve treatment efficacy while potentially lowering dose-dependent toxicity relative to single agents.
• Preventing drug resistance: Enables identification of combinations that reduce the likelihood of cancer cells developing resistance to therapy.
• Accelerating discovery of combinations: Integrates high-throughput screening data with informatics tools to systematically identify candidate synergistic drug combinations.

Methodology:

Aggregates and standardizes high-throughput drug combination screening data, applies linear regression models using chemical fingerprints as predictors to estimate combination sensitivity, and provides computational and visualization analyses of the standardized datasets.